IGCS 2024 Dublin: Highlights of research presented at the annual meeting
Authors:
- Florencia NollFNFlorencia Noll
- Aarthi JayrajAJAarthi Jayraj
- Geetu BhandoriaGBGeetu Bhandoria
- Teresa L. PanTPTeresa L. Pan
- Giuseppe CarusoGCGiuseppe Caruso
- Navya NairNNNavya Nair
- Irina TsibulakITIrina Tsibulak
- Luigi De VitisLVLuigi De Vitis
- Emma AllansonEAEmma Allanson
- Mine DaggezMDMine Daggez
- Raikhan BolatbekovaRBRaikhan Bolatbekova
- 9 May 2025
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (8) , 101931
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsJournal of Clinical Oncology, 2025
- The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trialAnnals of Oncology, 2024
- Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaThe Lancet, 2024
- Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2024
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialAnnals of Oncology, 2024
- Approach to radical hysterectomy for cervical cancer after the Laparoscopic Approach to Cervical Cancer trial and associated complications: a National Surgical Quality Improvement Program studyAmerican Journal of Obstetrics and Gynecology, 2024
- Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO studyGynecologic Oncology, 2024
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancerInternational Journal of Gynecological Cancer, 2021